DJIA 16,643.01 -11.76 -0.07%
NASDAQ 4,828.33 15.62 0.32%
S&P 500 1,988.87 1.21 0.06%
market minute promo

AstraZeneca plc (ADR) (NYSE: AZN)



company name or ticker
Company Photos
(Click to zoom)

Sosei Subsidiary Heptares, AstraZeneca Announce Agreement to Develop Novel Immuno-Oncology Treatment

Sosei Subsidiary Heptares, AstraZeneca Announce Agreement to Develop Novel Immuno-Oncology Treatments for Range of Cancers

Isis Pharmaceuticals Misses on Q2 Earnings and Revenues - Analyst Blog

Isis Pharmaceuticals Misses on Q2 Earnings and Revenues - Analyst Blog

What Company Will Be Fastest Growing Big-Cap Biotech?

AstraZeneca's MedImmune, Mirati Therapeutics Partner on Immuno-oncology Combination in Lung Cancer

Sell This Best-Of-Breed Pharma Major In The Short Term

Isis' News-Filled Week

The biotech announces a new partnership, clinical trial results, and earnings over the course of two days.

A Post-Earnings Review Of Amgen, With Discussion Of The Repatha Launch

Premarket Biotech Digest: Gilead HIV, Eliquis Trial Errors, Clinical Trial Phases

Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antis

Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOr Cardiovascular, Metabolic And Renal Disease

AstraZeneca, Isis Pharmaceuticals to Collaborate to Develop Antisense Drugs for Cardiovascular, Meta

AstraZeneca, Isis Pharmaceuticals to Collaborate to Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases
See More Articles...